Vaccine Breakthrough Stops Cancer Returning in Trial
4 Articles
4 Articles
Vaccine breakthrough stops cancer returning in trial
A personalized vaccine combined with an immunotherapy drug extended cancer-free survival in melanoma patients during a trial, though full results remain pending peer review and regulatory approval. The post Vaccine breakthrough stops cancer returning in trial appeared first on RocketNews.
"Intismeran Combines Immunotherapy and mRNA to Fight Skin Cancer"
An innovative treatment for skin cancer that merges immunotherapy with mRNA vaccine technology has shown promising outcomes in a late-phase trial, as per a joint announcement by pharmaceutical giants Merck and Moderna on Wednesday. The combined therapy, known as intismeran, outperformed standalone immunotherapy in curbing melanoma recurrence and preventing its spread in post-surgery melanoma patients. […] The post “Intismeran Combines Immunother…
Moderna and Merck’s personalized mRNA-based therapy has met key goals in a large-scale, phase III trial. The experimental treatment, combined with the immunotherapy Keytruda, reduced the risk of melanoma recurrence and distant spread. After more than a century of largely unsuccessful attempts, the first late-phase clinical trial of a therapeutic mRNA-based cancer vaccine has ended with a positive result. Moderna and […] The post Personalized can…
Pharmaceuticals Merck and Moderna claim to have revolutionary cancer therapy, a "therapeutic vaccine" that makes it difficult to come back...
Coverage Details
Bias Distribution
- 100% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
